180mg Xtc Pills

Product Beschrijving

Medical S-Isomer Ketamine (Esketamine hydrochloride) delivers the purified $(S)\text{-(+)}$ enantiomer of the arylcyclohexylamine derivative ketamine in standardized clinical formulations (e.g., Ketanest-S® injectable solution, Spravato® nasal spray). Clinically preferred over racemic mixtures in targeted settings due to higher clearance, lower required hypnotic dosages, and reduced post-anesthetic cognitive recovery intervals, medical S-ketamine modulates central glutamatergic pathways to deliver dual anesthetic and neurotrophic effects.

Clinical Profile & Pharmaceutical Formulations

• Active Pharmaceutical Ingredient: Esketamine Hydrochloride (equivalent to $(S)\text{-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one}$).

• Available Formulations:

  • Injectable Solution (Ketanest-S): Sterile aqueous solution (typically 5 mg/mL or 25 mg/mL) intended for slow intravenous (IV) or intramuscular (IM) administration in perioperative and emergency environments.

  • Intranasal Solution (Spravato): Single-use nasal spray devices delivering a precise 28 mg dose (two sprays, 14 mg per spray) utilizing a mucosal delivery matrix for psychiatric protocols.

• Hemodynamic Advantage: Provides robust surgical anesthesia and analgesia while preserving spontaneous airway reflexes and maintaining peripheral vascular tone via central sympathomimetic outflow, making it valuable in hemodynamic instability or shock.

Pharmacodynamics & Mechanism of Action

• NMDA Receptor Blockade: Functions as an uncompetitive, open-channel blocker of ionotropic $N$-methyl-D-aspartate (NMDA) glutamate receptors, binding to the phencyclidine site within the ion channel pore to arrest calcium ($\text{Ca}^{2+}$) influx.

• Glutamatergic Burst & Synaptic Plasticity: Transient inhibition of NMDA receptors on GABAergic interneurons induces a disinhibition of cortical pyramidal neurons. The resulting localized glutamate release stimulates post-synaptic $\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, triggering the secretion of brain-derived neurotrophic factor (BDNF) and activating the mammalian target of rapamycin (mTOR) pathway. This cascade promotes rapid synaptogenesis and restores spine density within the prefrontal cortex within hours.

• Secondary Targets: Exerts weak allosteric modulatory effects at opioid $\mu$ en $\kappa$ receptors, monoamine transporters (dopamine, serotonin, norepinephrine), and nicotinic acetylcholine receptors.

Pharmacokinetics & Metabolism

• Onset & Duration: IV induction induces surgical anesthesia within 30 to 60 seconds; intranasal administration achieves peak plasma concentrations ($C_{\max}$) within 20 to 40 minutes.

• Biotransformation: Extensively metabolized hepatically via cytochrome P450 enzymes (predominantly CYP2B6 and CYP3A4) through $N$-demethylation to active $(S)\text{-norketamine}$, which exhibits roughly one-third of the parent compound’s anesthetic activity. Subsequent hydroxylation and glucuronidation facilitate renal excretion.

• Elimination: Displays a mean terminal plasma elimination half-life of 2 to 4 hours, characterized by a rapid distribution phase ($\alpha$-phase) and comprehensive renal clearance.

Indications & Clinical Administration Protocols

• Treatment-Resistant Depression (TRD): Administered intranasally in conjunction with an oral antidepressant for adults with MDD who have not responded adequately to at least two different antidepressants, or for MDD with acute suicidal ideation.

• Anesthesia & Analgesia: Utilized as a sole anesthetic agent for diagnostic and short surgical procedures, as an induction agent prior to maintenance with other anesthetics, or as an opioid-sparing adjuvant for refractory perioperative pain.

• Strict Healthcare Monitoring (REMS): Due to the risks of serious adverse outcomes resulting from sedation and dissociation, psychiatric administration is restricted to certified healthcare facilities under a Risk Evaluation and Mitigation Strategy (REMS) program requiring at least two hours of post-administration clinical observation.

Important Safety Information & Boxed Warnings

• Sedation and Dissociation: Induces dose-dependent perceptual alterations, derealization, depersonalization, and profound sedation. Patients must be monitored by a healthcare provider until clinically stable.

• Cardiovascular Stimulation: Transient, significant elevations in systolic and diastolic blood pressure, as well as resting heart rate, frequently occur post-administration. Contraindicated in patients with severe aneurysmal vascular disease or uncontrolled hypertension.

• Abuse and Misuse: Classified as a Schedule III controlled substance due to potential for psychological and physiological dependence, misuse, and recreational diversion.

• Ulcerative Cystitis Risk: Chronic, high-frequency, non-medical exposure is associated with severe lower urinary tract pathology, including hemorrhagic cystitis, bladder wall fibrosis, and secondary hydronephrosis

Aanvullende Informatie